PDC*line Pharma’s Phase I/II Trial Primary Clinical Results Selected for Mini Oral Presentation at ESMO-IO 2024

PDC*line Pharma is thrilled to announce that the primary clinical analysis results from our Phase I/II trial (PDC-LUNG-101) will be presented as a mini oral presentation at the European Society for Medical Oncology - Immuno-Oncology Congress 2024 (ESMO-IO)! This study evaluates our innovative therapeutic cancer vaccine, PDC*lung01, in combination with anti-PD-1 for untreated stage IV Non-Small Cell Lung Cancer (NSCLC) patients. The congress will be held in Geneva, Switzerland, from December 11-13, 2024.
We’re honored that Prof. Johan F. Vansteenkiste (Leuven, Belgium) will present these results.

Mini Oral Presentation Details:
Title: Phase I/II trial evaluating the therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in untreated stage IV NSCLC patients
Abstract Number: 119MO
Session Title: Mini Oral Session 2
Date / Time: December 12, 2024, at 14:50 pm CEST

Note: ESMO-IO will publish all late-breaking abstracts online on December 10, 2024, at 00:05 CET via the ESMO website.

We look forward to contributing to the advancement of cancer immunotherapy at this esteemed event!

About ESMO and ESMO I-O

ESMO is the leading professional organisation for medical oncology. With more than 25,000 members representing oncology professionals from over 160 countries worldwide, ESMO is the society of reference for oncology education and information.

The ESMO Immuno-Oncology Congress is a global meeting offering an advanced educational programme and the latest scientific developments in this promising field.
https://www.esmo.org/meeting-calendar/esmo-immuno-oncology-congress-2024/